Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

314
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
314
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

491
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
491
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

298
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
298
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

288
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
288
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

63
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
63
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

4.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

More than a leaky gut: how gut priming shapes arthritis.

Nature reviews. Rheumatology·2025
Same author

Aberrant T follicular helper cells generated by T<sub>H</sub>17 cell plasticity in the gut promote extraintestinal autoimmunity.

Nature immunology·2025
Same author

PRMT5 Promotes T follicular helper Cell Differentiation and Germinal Center Responses during Influenza Virus Infection.

Journal of immunology (Baltimore, Md. : 1950)·2024
Same author

GAB functions as a bioenergetic and signalling gatekeeper to control T cell inflammation.

Nature metabolism·2022
Same author

<i>N</i>,<i>N</i>-Dimethyldithiocarbamate Elicits Pneumococcal Hypersensitivity to Copper and Macrophage-Mediated Clearance.

Infection and immunity·2022
Same author

Repeated Administration of 2-Hydroxypropyl-β-Cyclodextrin (HPβCD) Attenuates the Chronic Inflammatory Response to Experimental Stroke.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2021

Related Experiment Video

Updated: Nov 14, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

980

Methotrexate works remotely, from the gut.

Hsin-Jung Joyce Wu1

  • 1Department of Immunobiology, University of Arizona, Tucson, AZ 85719, USA; Arizona Arthritis Center, College of Medicine, University of Arizona, Tucson, AZ 85719, USA.

Cell Host & Microbe
|March 11, 2021
PubMed
Summary
This summary is machine-generated.

Methotrexate (MTX) reduces immune activation by altering the gut microbiota, offering a new explanation for its anti-inflammatory properties. This finding is crucial for understanding MTX

More Related Videos

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
06:04

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease

Published on: February 9, 2016

21.7K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.3K

Related Experiment Videos

Last Updated: Nov 14, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

980
Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
06:04

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease

Published on: February 9, 2016

21.7K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.3K

Area of Science:

  • Immunology
  • Microbiology
  • Pharmacology

Background:

  • Methotrexate (MTX) is a widely used anti-inflammatory drug.
  • The precise mechanisms underlying MTX's therapeutic effects are not fully understood.
  • Off-target effects of drugs can significantly influence their overall efficacy and safety profile.

Purpose of the Study:

  • To investigate the impact of methotrexate on immune activation.
  • To explore the role of the gut microbiota in mediating the effects of methotrexate.
  • To elucidate potential off-target mechanisms of methotrexate's anti-inflammatory action.

Main Methods:

  • In vivo studies using mouse models.
  • Analysis of immune cell populations and cytokine profiles.
  • 16S rRNA sequencing to assess gut microbiota composition.

Main Results:

  • Methotrexate treatment led to a reduction in systemic immune activation.
  • Significant alterations in the gut microbiota composition were observed following MTX administration.
  • Specific microbial taxa changes correlated with reduced inflammatory markers.

Conclusions:

  • Methotrexate exerts anti-inflammatory effects, in part, through modulating the gut microbiota.
  • Off-target effects on the gut microbiome represent a key mechanism for MTX's therapeutic action.
  • Targeting the gut microbiota could be a strategy to enhance MTX efficacy or mitigate side effects.